Kate McKinley Biography and Net Worth

Chief Business Officer of Rani Therapeutics

Kate comes to Rani with over 20 years of experience in the bio-pharmaceutical industry, including positions in executive leadership and as a board director. Kate has a demonstrated history of exceptional leadership, successfully steering executive teams, and driving corporate strategies to achieve remarkable business growth. Most recently, Kate was CEO and founder of Spark Lifesciences. Prior to joining Rani, Kate was also CEO and Board Director for Elvar Therapeutics (formerly known as LSK Biopharma), having previously been Elvar's Chief Commercial Officer and Chief Business Officer. She began her career at Abbvie Biopharmaceuticals / Abbot Laboratories where she served as Vice President of National Sales in the urology, oncology, and gynecology space. Kate is a summa cum laude graduate of The University of Tulsa. She holds an MBA from the university's Collins College of Business and a Bachelor of Science in Business Administration with degrees in Marketing, Management, and Psychology.

What is Kate McKinley's net worth?: The estimated net worth of Kate McKinley is at least $15.34 thousand as of December 13th, 2024. Ms. McKinley owns 17,960 shares of Rani Therapeutics stock worth more than $15,341 as of August 28th. This net worth approximation does not reflect any other assets that Ms. McKinley may own. Learn More about Kate McKinley's net worth.
How do I contact Kate McKinley?: The corporate mailing address for Ms. McKinley and other Rani Therapeutics executives is , , . Rani Therapeutics can also be reached via phone at 408-457-3700 and via email at [email protected]. Learn More on Kate McKinley's contact information.
Has Kate McKinley been buying or selling shares of Rani Therapeutics?: Kate McKinley has not been actively trading shares of Rani Therapeutics within the last three months. Most recently, on Friday, December 13th, Kate Mckinley bought 17,960 shares of Rani Therapeutics stock. The stock was acquired at an average cost of $1.67 per share, with a total value of $29,993.20. Following the completion of the transaction, the insider now directly owns 17,960 shares of the company's stock, valued at $29,993.20. Learn More on Kate McKinley's trading history.
Who are Rani Therapeutics' active insiders?: Rani Therapeutics' insider roster includes Alireza Javadi (Chief Technical Officer), and Kate McKinley (Chief Business Officer). Learn More on Rani Therapeutics' active insiders.
Are insiders buying or selling shares of Rani Therapeutics?: In the last year, Rani Therapeutics insiders bought shares 3 times. They purchased a total of 2,154,334 shares worth more than $1,300,040.40. In the last year, insiders at the sold shares 3 times. They sold a total of 5,923,386 shares worth more than $15,714,731.08. The most recent insider tranaction occured on July, 21st when Director Mir A Imran bought 36,000 shares worth more than $24,840.00. Insiders at Rani Therapeutics own 26.7% of the company. Learn More about insider trades at Rani Therapeutics.
Information on this page was last updated on 7/21/2026.

Kate McKinley Insider Trading History at Rani Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/13/2024	Buy	17,960	$1.67	$29,993.20	17,960

Kate McKinley Buying and Selling Activity at Rani Therapeutics

Rani Therapeutics Company Overview

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Today's Range

Now: $0.85

$0.85

$0.86

50 Day Range

MA: $0.78

$0.63

$0.92

2 Week Range

Now: $0.85

$0.44

$3.87

Volume

67,361 shs

Average Volume

995,417 shs

Market Capitalization

$117.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78